Intensive treatment of acute leukemia in adults 70 years of age and older

Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; Elihu H. Estey; Kenneth B. McCredie; Emil J. Freireich

doi:10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F

Intensive treatment of acute leukemia in adults 70 years of age and older

Ronald S. Walters, Hagop M. Kantarjian, Michael J. Keating, Elihu H. Estey, Kenneth B. McCredie, Emil J. Freireich

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Abstract

The results of treatment for acute leukemia since 1973 in 87 patients aged 70 years or more are summarized. The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m‐AMSA (amsacrine). The remission duration was short with a median of 33 weeks, and the median overall survival was only 6 weeks. Those patients without identifiable infection, liver enlargement, and a serum glutamic oxaloacetic transaminase < 40 U/ml constituted a more favorable subgroup. Although the complete remission rate improved further research is needed to develop effective maintenance strategies.

Original language	English (US)
Pages (from-to)	149-155
Number of pages	7
Journal	Cancer
Volume	60
Issue number	2
DOIs	https://doi.org/10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F
State	Published - Jul 15 1987

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F

Cite this

@article{e4598c4cd6d747f9b86770d2e27f7cb2,

title = "Intensive treatment of acute leukemia in adults 70 years of age and older",

abstract = "The results of treatment for acute leukemia since 1973 in 87 patients aged 70 years or more are summarized. The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m‐AMSA (amsacrine). The remission duration was short with a median of 33 weeks, and the median overall survival was only 6 weeks. Those patients without identifiable infection, liver enlargement, and a serum glutamic oxaloacetic transaminase < 40 U/ml constituted a more favorable subgroup. Although the complete remission rate improved further research is needed to develop effective maintenance strategies.",

author = "Walters, {Ronald S.} and Kantarjian, {Hagop M.} and Keating, {Michael J.} and Estey, {Elihu H.} and McCredie, {Kenneth B.} and Freireich, {Emil J.}",

year = "1987",

month = jul,

day = "15",

doi = "10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F",

language = "English (US)",

volume = "60",

pages = "149--155",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Intensive treatment of acute leukemia in adults 70 years of age and older

AU - Walters, Ronald S.

AU - Kantarjian, Hagop M.

AU - Keating, Michael J.

AU - Estey, Elihu H.

AU - McCredie, Kenneth B.

AU - Freireich, Emil J.

PY - 1987/7/15

Y1 - 1987/7/15

N2 - The results of treatment for acute leukemia since 1973 in 87 patients aged 70 years or more are summarized. The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m‐AMSA (amsacrine). The remission duration was short with a median of 33 weeks, and the median overall survival was only 6 weeks. Those patients without identifiable infection, liver enlargement, and a serum glutamic oxaloacetic transaminase < 40 U/ml constituted a more favorable subgroup. Although the complete remission rate improved further research is needed to develop effective maintenance strategies.

AB - The results of treatment for acute leukemia since 1973 in 87 patients aged 70 years or more are summarized. The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m‐AMSA (amsacrine). The remission duration was short with a median of 33 weeks, and the median overall survival was only 6 weeks. Those patients without identifiable infection, liver enlargement, and a serum glutamic oxaloacetic transaminase < 40 U/ml constituted a more favorable subgroup. Although the complete remission rate improved further research is needed to develop effective maintenance strategies.

UR - http://www.scopus.com/inward/record.url?scp=0023213880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023213880&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F

DO - 10.1002/1097-0142(19870715)60:2<149::AID-CNCR2820600204>3.0.CO;2-F

M3 - Article

C2 - 3474052

AN - SCOPUS:0023213880

SN - 0008-543X

VL - 60

SP - 149

EP - 155

JO - Cancer

JF - Cancer

IS - 2

ER -

Intensive treatment of acute leukemia in adults 70 years of age and older

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this